Skye Bioscience, Inc.
NGM: SKYELive Quote
📈 ZcoreAI Score
Our AI model analyzes Skye Bioscience, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get SKYE Z-Score →About Skye Bioscience, Inc.
Healthcare
Biotechnology
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
📊 Fundamental Analysis
Skye Bioscience, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -126.8%, which indicates that capital utilization is currently under pressure.
At a current price of $0.72, SKYE currently trades near the bottom of its 52-week range (3%), indicating potential value or weakness (Range: $0.57 - $5.75).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$24.03M
Trailing P/E
--
Forward P/E
-0.67
Beta (5Y)
2.87
52W High
$5.75
52W Low
$0.57
Avg Volume
560K
Day High
Day Low